Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index

Loredana Miglietta, Paola Vanella, Luciano Canobbio, Maria Angela Parodi, Pamela Guglielmini, Francesco Boccardo

Research output: Contribution to journalArticle

Abstract

Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression. Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.

Original languageEnglish
Pages (from-to)1621-1625
Number of pages5
JournalAnticancer Research
Volume29
Issue number5
Publication statusPublished - May 2009

Fingerprint

Breast Neoplasms
Drug Therapy
Neoadjuvant Therapy
Neoplasms
Therapeutics
Biomarkers
Incidence

Keywords

  • Biological markers
  • Locally advanced breast cancer
  • Neo-adjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. / Miglietta, Loredana; Vanella, Paola; Canobbio, Luciano; Parodi, Maria Angela; Guglielmini, Pamela; Boccardo, Francesco.

In: Anticancer Research, Vol. 29, No. 5, 05.2009, p. 1621-1625.

Research output: Contribution to journalArticle

@article{8b8daf9340ea458c96921cd77f651c01,
title = "Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index",
abstract = "Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression. Results: Overall, 30 patients (54{\%}) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20{\%}, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.",
keywords = "Biological markers, Locally advanced breast cancer, Neo-adjuvant chemotherapy",
author = "Loredana Miglietta and Paola Vanella and Luciano Canobbio and Parodi, {Maria Angela} and Pamela Guglielmini and Francesco Boccardo",
year = "2009",
month = "5",
language = "English",
volume = "29",
pages = "1621--1625",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index

AU - Miglietta, Loredana

AU - Vanella, Paola

AU - Canobbio, Luciano

AU - Parodi, Maria Angela

AU - Guglielmini, Pamela

AU - Boccardo, Francesco

PY - 2009/5

Y1 - 2009/5

N2 - Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression. Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.

AB - Objectives: Biological markers that reliably predict clinical and pathological response to primary systemic therapy may have considerable clinical potential; this study evaluated response compared to expression of ER, PgR and Her2, grading and Ki-67 proliferation index before and after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Patients and Methods: Fifty-five patients received neoadjuvant chemotherapy for LABC. The incidence of clinical and pathological responses was assessed with respect to basal clinical stage, absent/low vs. high ER and PgR status, low vs. high proliferation index, grading and Her2 overexpression. Results: Overall, 30 patients (54%) underwent downstaging of their primary tumor; pathological complete remission was observed in only one patient with Her2 positive breast tumor. Patients with pre-treatment Ki-67 >20%, Her2 overexpression, T2b/T3 vs. T4 clinical stage achieved higher response rate. Conclusion: The future of neoadjuvant therapy lies in tailoring treatment to individual patients by identifying response predictors; although the number of patients reported is small, this study confirms that clinical stage at diagnosis, Ki-67 reduction and Her2 overexpression are predictive of tumor response to neoadjuvant regimens.

KW - Biological markers

KW - Locally advanced breast cancer

KW - Neo-adjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=67650083191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650083191&partnerID=8YFLogxK

M3 - Article

C2 - 19443376

AN - SCOPUS:67650083191

VL - 29

SP - 1621

EP - 1625

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -